Salesforce.com to B...
Health Care: Drugs
Catalyst Pharmaceutical Partners Inc. (CPRX: NASDAQ)
$0.57 0.00 | 0.04%
06/04/12 - 03:54 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 41.40 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.71 | 0.46 | 0.98 |
| Price to Sales (TTM) | 0.00 | 2.04 | 1.42 |
| Price to Book (MRQ) | 5.19 | 2.63 | 2.41 |
| Price to Tangible Book (MRQ) | 5.19 | -21.74 | 5.08 |
| Price to Cash Flow (TTM) | -2.40 | 17.80 | 9.80 |
| Price to Free Cash Flow (TTM) | -2.60 | 38.30 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.60 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.30 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 0.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 14.20 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 10.80 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 19.65 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 116.90 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 116.90 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 1.26 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -39.13 | -1.90 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.40 | 1.10 | 1.10 |
| Current Ratio (MRQ) | 5.60 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.69 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.81 | 0.96 |
| Interest Coverage (TTM) | n.a. | 2.80 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 49.40 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 46.00 | 47.70 |
| EBITD Margin (TTM) | n.a. | 20.70 | 18.90 |
| EBITD - 5 Yr Avg | -7,856.72 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 7.40 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 0.50 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | n.a. | 0.06 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | -1.70 | 7.00 |
| Return on Assets (TTM) | -119.50 | 3.20 | 3.10 |
| Return on Assets - 5 Yr Avg | -66.30 | -0.80 | 2.50 |
| Return on Investment (TTM) | -219.00 | 4.50 | 7.90 |
| Return on Investment - 5 Yr Avg | -73.90 | -1.10 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 0.00 | 609,034.00 | 449,376.00 |
| Net Income/Employee (TTM) | -993,852.00 | 36,701.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 4.70 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 2.70 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.60 | 0.40 |
Portfolios with CPRX
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- UserSUPRATRADE EX-1006090013 DE...
- Userzhuangsn
- UserBRR Portfolio 1
- Userjaxplace Portfolio 1
- Usersovnek Portfolio 1
- UserDj Paul
- Userlouiis Portfolio 1
- Usercjthurman Portfolio 1
- Userajsny Portfolio 1
Latest CPRX Headlines from TheStreet
- 5 Stocks Setting Up to Break Out 12.20.11 | 01:12 pm
- Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 03.29.11 | 08:03 am
- Catalyst Pharmaceutical Partners To Present At The ROTH 23rd Annual OC Growth Stock Conference 03.09.11 | 11:03 am
- Catalyst Pharmaceutical Partners, Inc. Announces Public Offering Of Common Shares 03.08.11 | 09:03 am
- Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. To Chief Operating Officer 01.25.11 | 08:01 am
- Catalyst Pharmaceutical Partners To Present At The Biotech Showcase(TM) 2011 Conference 01.04.11 | 08:01 am
- Canadian Intellectual Property Office Grants Broad Patent For The Use Of Vigabatrin/CPP-109 For The Prevention Of Addiction In Pain Management 12.09.10 | 08:12 am
- Catalyst Pharmaceutical Partners Initiates A Registration-Directed U.S. Phase II(b) Clinical Trial In Collaboration With The National Institute On Drug Abuse And Veteran's Administration Cooperative Studies Program 11.18.10 | 08:11 am
- Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial And Operational Results 11.16.10 | 08:11 am
- Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners' Scientific Advisory Board 11.15.10 | 08:11 am
Press Releases for CPRX
- Vigabatrin/CPP-109 Data To Be Presented At College On Problems Of Drug Dependence Annual Meeting - PR Newswire 06.09.10 | 08:06 am
- Catalyst Pharmaceutical Partners To Present At The MoneyShow Conference - PR Newswire 05.07.10 | 08:05 am
- Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule - PR Newswire 04.26.10 | 11:04 am
- Catalyst Pharmaceutical Partners Signs Definitive Agreement With The National Institute On Drug Abuse To Conduct U.S. Phase II(B) Clinical Trial For Cocaine Addiction - PR Newswire 04.13.10 | 10:04 am
- CPP-109 Clinical Trial Data To Be Presented At The American Society Of Addiction Medicine Annual Medical-Scientific Conference - PR Newswire 04.09.10 | 08:04 am
- Catalyst Pharmaceutical Partners Reports Fourth Quarter And Year-End 2009 Financial Results - PR Newswire 04.01.10 | 08:04 am
- Catalyst Pharmaceutical Partners To Present At The BioNetwork East 2010 Conference - PR Newswire 03.10.10 | 08:03 am
- Catalyst Pharmaceutical Partners To Present Today At 2010 Epilepsy Pipeline Update Conference - PR Newswire 02.25.10 | 08:02 am
- Catalyst Pharmaceutical Partners And The National Institute On Drug Abuse Plan To Initiate U.S. Phase II(b) Clinical Trial For Cocaine Addiction - PR Newswire 02.23.10 | 08:02 am
- Catalyst Pharmaceutical Partners Selected To Present At Epilepsy Conference Highlighting New And Promising Therapies - PR Newswire 02.17.10 | 08:02 am
Partner Headlines for CPRX
- Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN - GuruFocus 06.04.12 | 01:06 pm
- 7 Stocks Under $6 Poised To Double In 2012 - Seeking Alpha 11.24.11 | 06:11 am
- 6 Biotechs That Could See Huge Gains (Like Inhibitex) - Seeking Alpha 11.11.11 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.14.11 | 09:10 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 10.10.11 | 09:10 am
- Morning Market Losers - Benzinga 06.06.11 | 09:06 am
- 7 Big Movers That Investors Must Watch This Week - Seeking Alpha 06.06.11 | 08:06 am
- 7 Dirt-Cheap Takeover Targets in Biotech - Seeking Alpha 06.03.11 | 09:06 am
- Orphan Status for Catalyst Drug - Analyst Blog - Zacks 09.22.10 | 06:09 pm
- Biotech's Slow Week Gets Stirred by a Few Smaller Deals - Seeking Alpha 08.15.10 | 04:08 am
